Study of weight gain medicine for teens with certain mood or psychosis
Treatments studied
Part of Mental health clinical trials.
This Phase 3 study tests a treatment aimed at reducing unhealthy weight gain in teens with schizophrenia or bipolar I disorder, using changes in BMI (a height-and-weight measure). It may help families who are concerned about weight changes that can happen with some psychiatric medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Aged 13–17 if you have schizophrenia, or aged 10–17 if you have bipolar I disorder
- You have a diagnosis that meets DSM-5 criteria (the mental health diagnosis system used in studies)
- You can be seen as an outpatient for study visits (or your doctor expects you can by Week 2)
- You have a reliable parent/guardian to help with outpatient care
- You are currently taking olanzapine, or you tried another antipsychotic but it didn’t work well or caused problems
- Your clinician believes you are not a danger to yourself or others
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks how safe a kid’s ongoing treatment is over a longer period. It is mainly for children who already finished a related study and may benefit from continuing the same medicines.
This trial tests a new combination tablet (olanzapine-samidorphan) for adults with schizophrenia. It aims to see if it helps control symptoms while potentially reducing weight gain, which can be a side effect of some schizophrenia medicines.
This study wants to see if a personalized approach with FDA-approved weight-loss medications can help people with bipolar disorder who are overweight or have obesity, while staying on their mood stabilizer treatment. It might be a good fit if you have bipolar disorder and struggle with your weight.
This study tests whether using a health app and smart body-fat scales helps people who are overweight or obese lose weight. It is designed for adults with bipolar disorder or schizophrenia who are stable and can safely follow the weight-loss and activity plan.
This Phase 1 trial tests whether BXCL501 is safe and can help reduce agitation in children and teens who have bipolar disorder or schizophrenia. You may be considered if your agitation is significant during screening, but certain recent medication and health factors can make you ineligible.
This trial tests a slower, lower-dose schedule of the drug olanzapine for people with schizophrenia. It aims to see if a gentler start is safer and works as well, especially for those who may need less medication due to other health conditions.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.